
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc operates within a growing market, with total ADHD medication sales in the U.S. experiencing an approximate annual growth rate of 8% since 2010, culminating in a market size of around $18 billion by 2020. In July 2023, the company released positive topline results from its CTx-1301 trial, indicating a favorable response among subjects compared to those receiving a placebo. The combination of a robust and expanding market alongside promising clinical trial outcomes suggests a significant upside potential for Cingulate's stock, indicating a positive outlook despite the inherent risks associated with biopharmaceutical development.
Bears say
Cingulate Inc reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which fell short of internal estimates of $(0.90) and consensus expectations of $(0.87). The company faces several significant risks that could affect its financial health and stock performance, including balance sheet and liquidity issues, the potential failure of product candidates in clinical trials, and challenges in securing regulatory approvals. Additionally, competition and macroeconomic factors, along with changing investor sentiment towards biotech investments, further contribute to a challenging outlook for Cingulate's stock.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares